Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone and Low Dose Methotrexate Protocol in Down Syndrome Children With ALL
NCT03286634Phase 2Active, not recruiting
- Sponsor
- National Hospital Organization Nagoya Medical Center
- Start
- Apr 2017
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, open-label trial of prednisolone and methotrexate in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by National Hospital Organization Nagoya Medical Center. Primary endpoint: Event Free Survival at 5 years. Started Apr 2017; status: active, not recruiting.
02
Drugs
prednisolonemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03286634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286634.